XML 64 R51.htm IDEA: XBRL DOCUMENT v2.4.0.8
Stockholders' Equity (Details) (USD $)
 0 Months Ended 1 Months Ended 12 Months Ended 0 Months Ended 0 Months Ended 1 Months Ended 12 Months Ended
Mar. 13, 2010
Oct. 31, 2010
Dec. 31, 2013
Dec. 31, 2012
Dec. 31, 2011
Feb. 28, 2013
Dec. 31, 2004
Oct. 31, 2010
Original public offering price [Member]
Dec. 13, 2010
Astellas Pharma Inc. [Member]
Apr. 09, 2012
Seaside 88, LP [Member]
Jul. 11, 2011
Seaside 88, LP [Member]
Closing
Apr. 30, 2012
Seaside 88, LP [Member]
Jul. 11, 2011
Seaside 88, LP [Member]
Initial Closing Period [Member]
Jul. 11, 2011
Seaside 88, LP [Member]
Every Two Weeks [Member]
Jul. 11, 2011
Seaside 88, LP [Member]
Ten Day Trading Period [Member]
Dec. 19, 2012
Lazard Capital Markets, LLC [Member]
Dec. 31, 2012
Lazard Capital Markets, LLC [Member]
Dec. 31, 2013
Lorem Vascular [Member]
Dec. 31, 2013
Lorem Vascular [Member]
First Closing of Stock sale [Member]
Dec. 31, 2013
Lorem Vascular [Member]
Second Closing of Stock sale [Member]
Preferred Stock [Abstract]                                        
Preferred stock, shares authorized (in shares)     5,000,000 5,000,000                                
Preferred stock, par value (in dollars per share)     $ 0.001 $ 0.001                                
Preferred stock, shares outstanding (in shares)     0 0                                
Common Stock [Abstract]                                        
Proceeds from private placement of stock   $ 20,700,000             $ 10,000,000   $ 6,000,000         $ 20,007,000 $ 3,000,000 $ 15,000,000 $ 12,000,000 $ 3,000,000
Common stock issued (in shares)   4,600,000             1,428,571 5,826,262 1,326,262         1,053,000 7,020,000 8,000,000 4,000,000 4,000,000
Additional shares of common stock (in shares)                                 1,053,000      
Common stock at a purchase price (in dollars per unit)               $ 4.50                 $ 2.85      
Sale of stock, price per share (in dollars per share)   $ 4.23             $ 7.00   $ 4.52           $ 2.69 $ 3.00    
Deferred revenues     212,000 2,635,000   2,379,000 1,500,000   2,526,000                      
Receivables from sale of stock                                   9,000,000    
Expected expiration period for recognition of deferred amount 2 years                                      
Common stock, shares issued (in shares)     71,305,375 65,914,050           5,826,262 6,326,262   1,326,262 250,000            
Purchase period of common stock                         30 days 14 days     30 days      
Number of closings                     20                  
Offering price per share (in dollars per share)   $ 4.23             $ 7.00   $ 4.52           $ 2.69 $ 3.00    
Purchase price of common stock, percent (in hundredths)                     88.00%       90.25%          
Trading period                     10 days                  
Proceeds from sale of common stock     $ 18,000,000 $ 24,953,000 $ 13,286,000         $ 18,233,000 $ 6,000,000                  
Number of shares terminated and not sold                       (500,000)